What could cause worsening menorrhagia in a 24-year-old woman?

Worsening Menorrhagia at Age 24: Evaluation and Management

You need a systematic evaluation to exclude structural uterine pathology (fibroids, polyps), bleeding disorders, and endocrine dysfunction before initiating treatment, with first-line medical therapy consisting of NSAIDs or combined oral contraceptives containing 30-35 μg ethinyl estradiol. 1

Initial Diagnostic Workup

Essential Laboratory Tests

• Complete blood count to assess for anemia (hemoglobin, hematocrit, and serum ferritin), as menstrual blood loss >80 mL/month progressively depletes iron stores 2, 3
• Pregnancy test to exclude pregnancy-related bleeding, even if you believe pregnancy is unlikely 1, 4
• Thyroid-stimulating hormone (TSH) level, as hypothyroidism can cause menorrhagia 2, 5
• Coagulation screening if clinically indicated: 11-40% of women with menorrhagia have an underlying bleeding disorder, most commonly von Willebrand disease (11.1%) or platelet function disorders (26.7%) 6, 3

Imaging and Structural Evaluation

• Transvaginal ultrasound is the first-line imaging modality to identify fibroids, adenomyosis, or endometrial polyps 7
• Consider saline infusion sonohysterography or hysteroscopy if ultrasound cannot adequately visualize the endometrium or if polyps/submucosal fibroids are suspected 7, 8
• Endometrial sampling is indicated if you are ≥45 years old, have risk factors for endometrial hyperplasia/cancer, or have failed medical therapy, though at age 24 this is less likely needed unless there are specific risk factors 7, 2

Rule Out Specific Causes

• Screen for sexually transmitted infections (chlamydia, gonorrhea), particularly in reproductive-aged women, as these can cause abnormal bleeding 1, 4
• Review all medications, especially psychotropics that cross the blood-brain barrier, anticoagulants, and any drugs that may interact with contraceptive hormones 4, 5
• Assess for cigarette smoking, which increases breakthrough bleeding risk 4

First-Line Medical Treatment

NSAIDs as Initial Therapy

Mefenamic acid 500 mg three times daily for 5-7 days during menstruation reduces menstrual blood loss by 20-60% and should be your first treatment attempt. 1, 8, 9 This approach is supported by systematic review evidence showing statistically significant reductions in mean menstrual blood loss 1

Combined Oral Contraceptives

If NSAIDs fail or if you prefer hormonal management, initiate monophasic combined oral contraceptives containing 30-35 μg ethinyl estradiol with levonorgestrel or norgestimate. 1 These work by inducing regular shedding of a thinner endometrium, reducing both blood loss and cramping 1

Additional benefits include improvement in acne and reduced risk of endometrial and ovarian cancers. 1

Important Safety Consideration

Before prescribing combined oral contraceptives, assess for thrombotic risk factors, as COCs increase venous thromboembolism risk 3-4 fold (up to 4 per 10,000 woman-years) 4. Contraindications include history of thrombosis, smoking >15 cigarettes/day if age >35, uncontrolled hypertension, or known thrombophilia 4

Management of Persistent Bleeding

If Bleeding Continues on Treatment

• Reassure that unscheduled bleeding is common during the first 3-6 months of hormonal therapy and is generally not harmful 1, 4
• Re-evaluate for underlying gynecological problems if bleeding persists beyond 3-6 months: check for medication interactions, new STIs, pregnancy, or newly developed uterine pathology 7, 4
• Add NSAIDs for 5-7 days during bleeding episodes if not already using them 7, 1
• Consider short-term hormonal treatment with low-dose COCs or estrogen for 10-20 days during bleeding episodes if medically eligible 7

Alternative Medical Options

Tranexamic acid reduces menstrual blood loss by 20-60% and is appropriate when hormonal treatment is contraindicated or if you desire immediate pregnancy, though it is contraindicated if you have active thromboembolic disease or history/risk of thrombosis 1, 8, 9

The levonorgestrel-releasing intrauterine system (LNG-IUS) reduces menstrual blood loss by 86-97%, with effectiveness comparable to endometrial ablation or hysterectomy, but requires 3-6 months to achieve maximal effect and causes irregular bleeding during the initial months 1, 9

When to Consider Procedural Intervention

If medical management fails to achieve acceptable control after appropriate trials, counsel about definitive options including endometrial ablation or, as a last resort, hysterectomy. 1 However, at age 24 with potential future fertility desires, these should be deferred until all medical options are exhausted 7, 5

Critical Counseling Points

Enhanced counseling about expected bleeding patterns reduces discontinuation rates and improves adherence. 1, 4 Specifically inform patients that:

• Irregular bleeding is most common in the first 3-6 months of any hormonal method 4
• These bleeding irregularities are generally not harmful 7, 1
• Symptoms typically improve with continued use 4

Common Pitfalls to Avoid

• Do not attribute worsening menorrhagia solely to "normal variation" without excluding structural pathology, as approximately 50% of women with menorrhagia have identifiable uterine abnormalities (fibroids in women <40 years, polyps in women >40 years) 8
• Do not delay coagulation screening in women with menorrhagia since menarche, family history of bleeding disorders, or other bleeding symptoms, as up to 40% may have an underlying bleeding disorder 6, 3
• Do not prescribe cyclic progestogens alone for ovulatory menorrhagia, as they do not significantly reduce menstrual bleeding in women who ovulate 8